AD has been shown to worsen about 6 months after the introduction of AChE inhibitors.[2,3] NMDA receptor antagonist is not indicated for mild AD as seen in the early stage, and no other pharmacological interventions at present are available for use until the disease state has progressed to a moderate or higher level in cases of redeterioration after AChE inhibitor introduction. The gene discussed is ACHE; the disease is Alzheimer disease.